Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 10/20 | 1.00 |
| ▸ | DRD2 | P14416 | 7/20 | 0.57 |
| ▸ | DRD4 | P21917 | 7/20 | 0.57 |
| ▸ | DRD3 | P35462 | 5/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17615422 | 0.90 | ERN1 (0.82) | ERN1DRD2DRD4DRD3KDM4E | |
| SCHEMBL17601909 | 0.90 | ERN1 (1.00) | ERN1DRD2DRD4DRD3 | |
| SCHEMBL16197847 | 0.80 | ERN1 (1.00) | ERN1DRD2DRD4DRD3KDM4E | |
| SCHEMBL17601922 | 0.77 | ERN1 (1.00) | ERN1KDM4EALDH1A1GLAGAA | |
| SCHEMBL17615419 | 0.75 | ERN1 (0.70) | ERN1KDM4EALDH1A1GLAGAA | |
| SCHEMBL21101440 | 0.75 | ERN1 (0.74) | ERN1DRD2DRD4DRD3KDM4E | |
| SCHEMBL17601914 | 0.75 | ERN1 (1.00) | ERN1KDM4EALDH1A1GLAGAA | |
| SCHEMBL17615420 | 0.74 | ERN1 (0.68) | ERN1KDM4EALDH1A1GLAGAA | |
| SCHEMBL17615429 | 0.74 | ERN1 (0.68) | ERN1KDM4EALDH1A1GLAGAA | |
| SCHEMBL16197814 | 0.74 | ERN1 (1.00) | ERN1KDM4EALDH1A1GLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294487-A1 | INHIBITORS OF THE IRE-1/XBP-1 PATHWAY AND METHODS OF USING THEREOF | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2024-09-05 | — | — | US | disclosed |
| US-11945789-B2 | Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| US-20230107770-A1 | METHOD OF ENHANCING IMMUNOTHERAPY USING ER STRESS PATHWAY INHIBITORS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-04-06 | — | — | US | disclosed |
| US-10323013-B2 | Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-10323013-B2 | Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-20160083361-A1 | INHIBITORS OF THE IRE-1/XBP-1 PATHWAY AND METHODS OF USING THEREOF | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20160083361-A1 | INHIBITORS OF THE IRE-1/XBP-1 PATHWAY AND METHODS OF USING THEREOF | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10323013-B2 | Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof | XBP1, ERN1, SREBF1 | ERN1 2/4885DRD2 4261/4885DRD4 4683/4885 |
| US-20160083361-A1 | INHIBITORS OF THE IRE-1/XBP-1 PATHWAY AND METHODS OF USING THEREOF | XBP1, RRP1B, ERN1 | ERN1 3/4885DRD2 4109/4885DRD4 4378/4885 |
| US-11945789-B2 | Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof | XBP1, DDIT3, ERN1 | ERN1 3/4885DRD2 4806/4885DRD4 4766/4885 |
| US-20240294487-A1 | INHIBITORS OF THE IRE-1/XBP-1 PATHWAY AND METHODS OF USING THEREOF | XBP1, DDIT3, ERN1 | ERN1 3/4885DRD2 4806/4885DRD4 4766/4885 |
| US-20230107770-A1 | METHOD OF ENHANCING IMMUNOTHERAPY USING ER STRESS PATHWAY INHIBITORS | DDIT3, NFATC1, MCL1 | ERN1 57/4885DRD2 4670/4885DRD4 4717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.